Unlock instant, AI-driven research and patent intelligence for your innovation.

a medicine for asthma

A technology for asthma and drugs, applied in the field of drugs for the treatment of asthma, can solve the problems of complex pathogenesis of asthma and limited therapeutic effect, and achieve the effects of preventing asthma attacks, inhibiting release, and relieving symptoms

Active Publication Date: 2020-02-28
JIANGSU KANION PHARMA CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The pathogenesis of asthma is complex, there is no complete cure, and the existing drug treatments have limited effects, so it is of great significance to develop new drugs for the treatment of asthma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • a medicine for asthma
  • a medicine for asthma
  • a medicine for asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 The inhibitory activity of oxidized loganin to 5-lipoxygenase (5-LOX)

[0020] 1.1. Experimental materials

[0021] Reagents: recombinant human 5-lipoxygenase (humanrecombinant5-LOX) (cayman, cat60402), arachidonic acid (cayman, cat90010), H 2 DCFDA (sigma, catD6883), NDGA (cayman, cat70300), Tris (biocam, cat0479), CaCl 2 (Nanjing Chemical Reagent Co., Ltd.), Na 2 ATP (sigma, catA2383), deoxygenated loganin (Shanghai Fengshou Reagent Co., Ltd.), DMSO (sigma, D2650), Milli-QH 2 O.

[0022] Instrument Microplate reader (moleculardevicesspectraMaxM2e), pipette gun (eppendorf), micro-oscillator (Guohua ZW-A), electric heating constant temperature blast drying oven (Shanghai Jinghong DHG-9023), -70 ℃ refrigerator (HaierDW-86L286 type ), -20°C refrigerator (SIMENSBCD-254), pH meter (Mettler Toledo FE20 type), balance (Mettler Toledo AL104), detection plate (corning, cat3712), sealing film at the bottom of the detection plate (perkinelmer, cat6005199)

[0023] ...

Embodiment 2

[0030] Therapeutic effect of embodiment 2 intragastric (oral) administration of oxidized loganin on guinea pigs with asthma

[0031] 2.1 Experimental materials:

[0032] Reagent: Asthma-inducing agent: 10mg histamine phosphate, 0.2g acetylcholine chloride, add physiological saline to make 100ml mixed solution (concentration is 0.2% acetylcholine chloride and 0.01% phosphate histamine), prepare before use. Qiliutong was purchased from Hubei Shengtian Hengchuang Biotechnology Co., Ltd.

[0033] Animal guinea pig, Qinglongshan Animal Breeding Farm.

[0034] 2.2 Experimental method:

[0035] Modeling: On the first day, use histamine phosphate combined with acetylcholine chloride to challenge the guinea pigs through the YLS-8A cough and asthma device for 4 minutes, record the asthma latency (s) of the guinea pig convulsions, and combine the symptoms of the guinea pigs within 4 minutes to test the guinea pigs. Asthma grade (asthma grade: grade 1-exacerbation of breathing; grade 2...

Embodiment 3

[0042] Example 3 Therapeutic Effect of Injection of Broken Oxidized Loganin on Asthmatic Rats

[0043] 3.1 Experimental materials:

[0044] Reagents Dexamethasone Sodium Phosphate Injection (5mg / m1) (Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.); Sodium Hydroxide (Nanjing Chemical Reagents); Ovalbumin (OVA, Sigma, USA)

[0045] Animals 40 clean-grade SD rats, all male, with a body mass of 260±20) g, were purchased from Qinglongshan Animal Breeding Farm.

[0046] 3.2 Experimental method:

[0047] Modeling: SD rats were randomly divided into normal control group, asthma model group, high-dose, medium-dose and low-dose groups of oxidized loganin, and fuxotide aerosol group, with 8 rats in each group. Except for the normal control group, each rat in the other three groups was intraperitoneally injected with 1mL of LOVA solution (1mg of OVA + 200mg of aluminum hydroxide + 1mL of normal saline suspension) to sensitized animals on the first day and the eighth day of model...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for treating asthma. The medicine for treating asthma contains secoxyloganin, comprises other therapeutic agents and further contains pharmaceutically acceptable carriers. The medicine for treating asthma is an oral agent, an inhalant or an injection, and the oral agent is in a form of powder, tablets, granules, capsules, solutions, emulsions or suspensions. The medicine has the benefits as follows: asthmatic attack is prevented or symptoms of acute attack are relieved through inhibition of release of leukotrienes as an inflammatory factor.

Description

technical field [0001] The invention belongs to the technical field of asthma treatment, in particular to a medicine for treating asthma. Background technique [0002] Bronchial asthma (asthma for short) is a chronic airway inflammatory disease with complex pathogenesis. Clinically, it is mainly manifested as recurrent wheezing, shortness of breath, chest tightness, coughing and other symptoms. A small number of patients may also have chest pain. Dyspnea and sudden death may occur. Asthma is one of the most common chronic diseases worldwide, and its prevalence has been increasing year by year in recent years. The pathogenesis of asthma is complicated, and there is no complete cure for it at present, and the effect of existing drugs is limited, so it is of great significance to develop new drugs for the treatment of asthma. [0003] Leukotrienes (LTs) are important inflammatory mediators in the pathogenesis of bronchial asthma. They participate in the chronic inflammatory p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P11/06
CPCA61K9/0078A61K31/7048
Inventor 萧伟苏真真曹泽彧李娜曹亮王振中丁岗
Owner JIANGSU KANION PHARMA CO LTD